GCM
CYTK icon

Ghisallo Capital Management’s Cytokinetics CYTK Stock Holding History

Ghisallo Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Buy
+170,000
New +$12.2M 0.28% 67
2024
Q3 		– Sell
-196,000
Closed -$10.6M – 153
2024
Q2 		$10.6M Buy
+196,000
New +$11.8M 0.92% 26

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ghisallo Capital Management's CYTK Position: Q2 2026 in Review

Ghisallo Capital Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 170,000 shares worth $14.5M. The stake represents 0.28% of the portfolio and ranks #67 among its holdings. This is a return to the name: Ghisallo Capital Management previously reported a position in CYTK as recently as Q2 2024.

Ghisallo Capital Management first reported a position in CYTK in Q2 2024 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ghisallo Capital Management held 170,000 shares of Cytokinetics worth $14.5M as of Q2 2026.
  • Cytokinetics was a new Ghisallo Capital Management position in Q2 2026.
  • Cytokinetics made up 0.28% of Ghisallo Capital Management's portfolio in Q2 2026, its #67 holding.
  • Ghisallo Capital Management first reported a position in Cytokinetics in Q2 2024 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.